linicians now have a better picture of what may be the optimal first-line therapy for patients with metastatic non-clear cell renal cell carcinoma (NC-RCC), according to results from a randomized phase 2 international trial of everolimus compared with sunitinib. Investigators reported at the 2015 American Society of Clinical Oncology Annual Meeting that sunitinib was superior […]